ArticleLa Radiologia medica2021
Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice.
Article in La Radiologia medica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Radiotherapy based management during Covid-19 pandemic - A systematic review of presented consensus and guidelines.Critical reviews in oncology/hematology · 2021Pooled it
- Diffusion kurtosis imaging and standard diffusion imaging in the magnetic resonance imaging assessment of prostate cancer.Gland surgery · 2023Review
- Radiomics and machine learning analysis by computed tomography and magnetic resonance imaging in colorectal liver metastases prognostic assessment.La Radiologia medica · 2023Article
- Prognostic Assessment of Gastropancreatic Neuroendocrine Neoplasm: Prospects and Limits of Radiomics.Diagnostics (Basel, Switzerland) · 2023Review
- Qualitative and semi-quantitative ultrasound assessment in delta and Omicron Covid-19 patients: data from high volume reference center.Infectious agents and cancer · 2023Article
- Colorectal liver metastases patients prognostic assessment: prospects and limits of radiomics and radiogenomics.Infectious agents and cancer · 2023Review
- Dose Reduction Strategies for Pregnant Women in Emergency Settings.Journal of clinical medicine · 2023Review
- Exploring Radiologists' Burnout in the COVID-19 Era: A Narrative Review.International journal of environmental research and public health · 2023Review
- Post-Surgical Imaging Assessment in Rectal Cancer: Normal Findings and Complications.Journal of clinical medicine · 2023Review
- Radiation Recall Pneumonitis: The Open Challenge in Differential Diagnosis of Pneumonia Induced by Oncological Treatments.Journal of clinical medicine · 2023Review
- Article
- Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence.Biology · 2023Review
- Immunotherapy Assessment: A New Paradigm for Radiologists.Diagnostics (Basel, Switzerland) · 2023Review
- Imaging Features of Main Hepatic Resections: The Radiologist Challenging.Journal of personalized medicine · 2023Review
- Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence.Cancers · 2023Review
- Percutanous Electrochemotherapy (ECT) in Primary and Secondary Liver Malignancies: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Integration between Novel Imaging Technologies and Modern Radiotherapy Techniques: How the Eye Drove the Chisel.Cancers · 2022Review
- A year of pandemic for European particle radiotherapy: A survey on behalf of EPTN working group.Clinical and translational radiation oncology · 2022Article
- Covid-19 and radiotherapy: a systematic review after 2 years of pandemic.Clinical and translational imaging · 2022Review
- The Impact of the SARS-CoV-2 Pandemic on Healthcare Provision in Italy to non-COVID Patients: a Systematic Review.Mediterranean journal of hematology and infectious diseases · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo evaluate stereotactic body radiotherapy (SBRT) in low-risk Prostate Cancer patients as preferred treatment option in emergency health conditions. MATERIALS AND
methodsFrom April 2013 to September 2015, 28 patients with low-risk prostate cancer were prospectively enrolled. The SBRT prescribed dose was 36.25 Gy in 5 fractions, twice a week. Primary endpoints were acute and late toxicity. Secondary endpoints were biochemical recurrence free survival (bRFS) and overall survival.
resultsMedian follow-up was 65.5 months (range 52-81). No acute G3 or G4 toxicity was recorded. Acute G1 or G2 genitourinary (GU) toxicity occurred in 43% and acute G1-G2 gastrointestinal (GI) toxicity in 14%. Late G1 and G3 GU toxicity in 18% and 3.5%, respectively. The G3 toxicity was not directly attributable to radiotherapy. Late G1 GI toxicity occurred in 18%. 5yy bRFS was 96.5% (95% CI 82.3-99.4%).
conclusionsStereotactic body radiotherapy for early prostate cancer reported safe toxicity profile and a good clinical outcome at the median follow-up of 5 years. It may be an useful option if radiotherapy is required in emergency medical conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.